Comparison of Emapalumab with Conventional Treatment in Patients with Primary Hemophagocytic Lymphohistiocytosis (HLH): Consistent Results Obtained in an Unadjusted and an Adjusted Analysis

Primary HLH is a rare, genetic immune-mediated disorder characterized by severe immune activation and hyperinflammation. It is associated with progressive immune-mediated organ damage and is fatal if untreated.